<code id='712F32516D'></code><style id='712F32516D'></style>
    • <acronym id='712F32516D'></acronym>
      <center id='712F32516D'><center id='712F32516D'><tfoot id='712F32516D'></tfoot></center><abbr id='712F32516D'><dir id='712F32516D'><tfoot id='712F32516D'></tfoot><noframes id='712F32516D'>

    • <optgroup id='712F32516D'><strike id='712F32516D'><sup id='712F32516D'></sup></strike><code id='712F32516D'></code></optgroup>
        1. <b id='712F32516D'><label id='712F32516D'><select id='712F32516D'><dt id='712F32516D'><span id='712F32516D'></span></dt></select></label></b><u id='712F32516D'></u>
          <i id='712F32516D'><strike id='712F32516D'><tt id='712F32516D'><pre id='712F32516D'></pre></tt></strike></i>

          Home / entertainment / leisure time

          leisure time


          leisure time

          author:fashion    Page View:17518
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In